These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21707612)

  • 1. Comparison of different bile acid-phospholipid conjugates in acute hepatitis.
    Pathil A; Warth A; Chamulitrat W; Stremmel W
    Eur J Clin Invest; 2012 Feb; 42(2):130-8. PubMed ID: 21707612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury.
    Pathil A; Warth A; Chamulitrat W; Stremmel W
    J Hepatol; 2011 Apr; 54(4):674-84. PubMed ID: 21146893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury.
    Ludwig JM; Zhang Y; Chamulitrat W; Stremmel W; Pathil A
    PLoS One; 2018; 13(5):e0197836. PubMed ID: 29795632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
    Chamulitrat W; Burhenne J; Rehlen T; Pathil A; Stremmel W
    Hepatology; 2009 Jul; 50(1):143-54. PubMed ID: 19496180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia and reperfusion injury in mice.
    Wang J; Deng X; Yi S; Pathil A; Zhang W; Setchell K; Stremmel W; Chamulitrat W
    Shock; 2015 Apr; 43(4):379-86. PubMed ID: 25526375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.
    Pathil A; Mueller J; Ludwig JM; Wang J; Warth A; Chamulitrat W; Stremmel W
    Br J Pharmacol; 2014 Nov; 171(22):5113-26. PubMed ID: 25041068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis.
    Utaipan T; Otto AC; Gan-Schreier H; Chunglok W; Pathil A; Stremmel W; Chamulitrat W
    Shock; 2017 Aug; 48(2):251-259. PubMed ID: 28060213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes.
    Chamulitrat W; Liebisch G; Xu W; Gan-Schreier H; Pathil A; Schmitz G; Stremmel W
    Mol Pharmacol; 2013 Nov; 84(5):696-709. PubMed ID: 23974795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia/reperfusion injury via phospholipid metabolism-mediated mitochondrial quality control.
    Gu J; Zhang T; Guo J; Chen K; Wang G; Li H; Wang J
    FASEB J; 2020 May; 34(5):6198-6214. PubMed ID: 32162746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization.
    Su J; Gan-Schreier H; Goeppert B; Chamulitrat W; Stremmel W; Pathil A
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholyl lysophosphatidylethanolamide negatively regulates TLR-mediated lipopolysaccharide response in human THP-1-derived macrophages.
    Horvatova A; Utaipan T; Otto AC; Zhang Y; Gan-Schreier H; Pavek P; Pathil A; Stremmel W; Chamulitrat W
    Eur J Pharmacol; 2018 Apr; 825():63-74. PubMed ID: 29475064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl-Lysophosphatidylethanolamide (UDCA-LPE) Disintegrates the Lipid Backbone of Raft Plasma Membrane Domains by the Removal of the Membrane Phospholipase A2.
    Stremmel W; Staffer S; Fricker G; Weiskirchen R
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
    Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
    J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate.
    Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A
    Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatoprotectant ursodeoxycholyl lysophosphatidylethanolamide increasing phosphatidylcholine levels as a potential therapy of acute liver injury.
    Chamulitrat W; Zhang W; Xu W; Pathil A; Setchell K; Stremmel W
    Front Physiol; 2012; 3():24. PubMed ID: 22363296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells.
    Lim SC; Duong HQ; Choi JE; Lee TB; Kang JH; Oh SH; Han SI
    Carcinogenesis; 2011 May; 32(5):723-31. PubMed ID: 21362627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats.
    Nowak G; Norén UG; Wernerson A; Marschall HU; Möller L; Ericzon BG
    Transpl Int; 2005 May; 17(12):804-9. PubMed ID: 15815896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
    Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
    J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.